Lucence at ESMO Asia 2022

Suntec Singapore, Booth E207
2-4 December, 2022

Book Meeting

scroll-arrow

From the CEO

Friends and colleagues,

Please join us at the ESMO Asia Congress 2022, organised by the European Society for Medical Oncology, from 2-4 December 2022. On this page you’ll find information on our latest news and updates we will be sharing.

We’re excited to partner pharmas and physicians to improve patient access by advanced, affordable and accurate next-generation sequencing (NGS) testing. Our team will be present at booth E207 and we hope you will get in touch.

We’re looking forward to seeing you in person.

Gratefully,

Min Han Tan

news-image1 news-image2

News

Lucence shares results of NGS test performance on CSF specimen of lung cancer patients during ESMO Asia Congress 2022.

Read Release Here

Abstracts for ESMO Asia 2022

2 December 2022
Liquid biopsy NGS test identifies actionable DNA mutations from CSF specimens of lung cancer patients.

Authors:

Daniel BY Chan 1, TM Chin 2, John WL Chia 3, Jacky YC Li 4,  Janice WH Tsang 5, Jonathan Poh 6, Christopher W Wong 6, Min-Han Tan 6, .

 

1 Icon Cancer Centre, Singapore; 2 Parkway Cancer Centre, Singapore; 3 Curie Oncology, Singapore; 4 Hong Kong Baptist Hospital, Hong Kong SAR, China ; 5 Hong Kong United Oncology Centre, and Gleneagles Hong Kong, Hong Kong SAR, China; 6 Lucence Diagnostics Pte Ltd, Singapore.

 

Abstract -

Poster number: -

Book a meeting

Lucence is glad to share how accurate and affordable ctDNA and ctRNA panels speeds drug development and improves access.

Dr. Min-Han Tan CEO & Medical Director

Ms. Hilda Tan Head, Sales & Marketing (Oncology Services)

Book a meeting with us today

Get Updates

Sign up for the latest news and updates about Lucence at ESMO Asia 2022. For questions, email us at [email protected].